Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer
Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerAbsolute lymphocyte countAbsolute neutrophil countLow-risk prostate cancer patientsProstate cancer patientsProstate cancerLymphocyte countANC groupLymphocyte ratioBiochemical recurrenceCancer patientsActive surveillanceHigher prostate-specific antigen levelMetastatic castration-resistant prostate cancerLow-risk PCa patientsProstate-specific antigen levelHigh absolute lymphocyte countCastration-resistant prostate cancerBiochemical recurrence-free survivalRobot-assisted radical prostatectomyAdverse pathologic outcomesAppropriate patient selectionKaplan-Meier methodRecurrence-free survivalRisk stratification tool